Ciclosporin A ophthalmic - Laboratorios Sophia/Alcon

Drug Profile

Ciclosporin A ophthalmic - Laboratorios Sophia/Alcon

Alternative Names: Alcon; Cyclosporine opthalmic solution; ST-603; Zyclorin

Latest Information Update: 05 Aug 2013

Price : $50

At a glance

  • Originator Laboratorios Sophia
  • Developer Alcon
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Dry eyes

Most Recent Events

  • 30 Mar 2013 Discontinued - Phase-III for Dry eyes in USA (Topical)
  • 30 Mar 2012 No development reported - Phase-III for Dry eyes in USA (Topical)
  • 26 Aug 2010 Alcon has been acquired by Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top